THE NHS is failing to keep up with science, experts blasted after breakthrough new dementia drugs were rejected again by the regulator. Charities and scientists said patients are being left behind ...

Donanemab is being trialed in the Colombian kindred, Down’s syndrome. Baseline plaque load best predicts amyloid clearance on donanemab. The fluid biomarker MTBR-243 tau tracks tangle response to ...

On new studies, Lilly scientists presented efforts to gather real-world data on donanemab’s effectiveness, and debuted the Phase 3 trial design for donanemab’s successor, remternetug, which patients ...

Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid plaques in the brain. Learn their differences.

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said. The National Institute ...

In May of 2023, two months prior to the full approval of lecanemab, another promising treatment for the disease, Eli Lilly’s donanemab, emerged from Phase III trials.

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

Discover breaking news detailing why the NHS will not cover two new Alzheimer’s drugs due to the high annual costs.

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS. The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Lecanemab and donanemab were approved by the UK's safety regulator the MHRA in 2024, but are not currently available on the NHS, amid discussion about their cost-effectiveness.

NICE has once again rejected new drugs for early Alzheimer’s disease because the costs are too great to justify the small ...